Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
| NBY Stock | USD 0.81 0.10 14.08% |
Slightly above 55% of NovaBay Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading NovaBay Pharmaceuticals stock suggests that some investors are interested at this time. NovaBay Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, NovaBay Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
NovaBay |
Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transitionNEW YORK, Sept. 03, 2024 -- Eyenovia, Inc. , a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of divers
Read at finance.yahoo.com
 |
NovaBay Pharmaceuticals Fundamental Analysis
We analyze NovaBay Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NovaBay Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NovaBay Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
NovaBay Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
NovaBay Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NovaBay Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of NovaBay Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NovaBay Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
NovaBay Pharmaceuticals Related Equities
| SONN | Sonnet Biotherapeutics | 29.87 | ||||
| ZURA | Zura Bio | 1.13 | ||||
| IMMX | Immix Biopharma | 0.51 | ||||
| ENVB | Enveric Biosciences | 2.94 | ||||
| PALI | Palisade Bio | 5.30 | ||||
| ZVSA | ZyVersa Therapeutics | 5.41 | ||||
| PHIO | Phio Pharmaceuticals | 7.66 |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.